Patents Assigned to Andrx Corporation
-
Patent number: 7713550Abstract: Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.Type: GrantFiled: June 15, 2004Date of Patent: May 11, 2010Assignee: Andrx CorporationInventors: Nilobon Podhipleux, Xiu Xiu Cheng, Unchalee Lodin, Chih-Ming Chen, Avinash Nangia, Dacheng Tian
-
Publication number: 20070184078Abstract: In certain embodiments, the invention is directed to a package for dispensing a combination of a proton pump inhibitor and a non-steroidal anti-inflammatory drug.Type: ApplicationFiled: January 16, 2007Publication date: August 9, 2007Applicant: Andrx CorporationInventor: Chih-Ming Chen
-
Publication number: 20070160671Abstract: In certain embodiments, the invention is directed to a pharmaceutical dosage form consisting essentially of a single phase matrix comprising metformin or a pharmaceutically acceptable salt thereof and at least one controlled release excipient; said dosage form providing a mean Tmax of metformin from about 3 to about 12 hours after administration to human patients.Type: ApplicationFiled: March 16, 2007Publication date: July 12, 2007Applicant: Andrx CorporationInventors: Xiu-Xiu Cheng, Chih-Ming Chen, Steve Jan, Dacheng Tian
-
Patent number: 7022342Abstract: A sustained release beta-adrenergic receptor blocking agent, preferably propranolol, formulation.Type: GrantFiled: March 28, 2002Date of Patent: April 4, 2006Assignee: Andrx Corporation, Inc.Inventors: Chih-Ming Chen, Xiu Xiu Cheng
-
Publication number: 20060008526Abstract: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Type: ApplicationFiled: September 13, 2005Publication date: January 12, 2006Applicant: Andrx CorporationInventors: Chih-Ming Chen, Xiu-Xiu Cheng, Steve Jan, Joseph Chou
-
Publication number: 20060008525Abstract: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Type: ApplicationFiled: September 13, 2005Publication date: January 12, 2006Applicant: Andrx CorporationInventors: Chih-Ming Chen, Xiu-Xiu Cheng, Steve Jan, Joseph Chou
-
Publication number: 20060008523Abstract: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Type: ApplicationFiled: September 13, 2005Publication date: January 12, 2006Applicant: Andrx CorporationInventors: Chih-Ming Chen, Xiu-Xiu Cheng, Steve Jan, Joseph Chou
-
Publication number: 20060008524Abstract: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Type: ApplicationFiled: September 13, 2005Publication date: January 12, 2006Applicant: Andrx CorporationInventors: Chih-Ming Chen, Xiu-Xiu Cheng, Steve Jan, Joseph Chou
-
Publication number: 20050027011Abstract: A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.Type: ApplicationFiled: December 23, 2003Publication date: February 3, 2005Applicant: Andrx CorporationInventors: Chih-Ming Chen, Boyong Li, Janice Cacace
-
Patent number: 6720003Abstract: A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.Type: GrantFiled: February 16, 2001Date of Patent: April 13, 2004Assignee: Andrx CorporationInventors: Chih-Ming Chen, Boyong Li, Janice Cacace
-
Patent number: 6683112Abstract: The present invention relates to novel prodrugs of gabapentin and to pharmaceutical formulations and sustained release formulations containing the prodrugs.Type: GrantFiled: October 23, 2001Date of Patent: January 27, 2004Assignee: Andrx CorporationInventors: Chih-Ming Chen, Jane Chen
-
Patent number: 6610326Abstract: A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.Type: GrantFiled: February 16, 2001Date of Patent: August 26, 2003Assignee: Andrx CorporationInventors: Chih-Ming Chen, Boyong Li
-
Patent number: 6544556Abstract: An oral solid dosage form includes a therapeutically effective amount of an NSAID and a proton pump inhibitor in an amount effective to inhibit or prevent gastrointestinal side effects normally associated with the NSAID. Also disclosed is a method of treating a human patient in need of antiinflammatory, analgesic and/or antipyretic therapy, comprising orally administering to the patient an oral pharmaceutical dosage form which includes a therapeutically effective amount of an NSAID and an amount of a proton pump inhibitor effective to substantially inhibit gastrointestinal side effects of the NSAID. The invention is further related to a method of prophylactically treating a human patient who is on a therapy known to have significant gastrointestinal side effects or is about to begin such a therapy, via concurrent administration of an NSAID and a proton pump inhibitor in a combination (single) oral dosage form.Type: GrantFiled: September 11, 2000Date of Patent: April 8, 2003Assignee: Andrx CorporationInventors: Chih-Ming Chen, Unchalee Kositprapa
-
Publication number: 20020156066Abstract: A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.Type: ApplicationFiled: February 16, 2001Publication date: October 24, 2002Applicant: Andrx CorporationInventors: Chih-Ming Chen, Boyong Li, Janice Cacace
-
Publication number: 20020115718Abstract: A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.Type: ApplicationFiled: February 16, 2001Publication date: August 22, 2002Applicant: Andrx CorporationInventors: Chih-Ming Chen, Boyong Li
-
Publication number: 20010024659Abstract: Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.Type: ApplicationFiled: November 29, 2000Publication date: September 27, 2001Applicant: Andrx CorporationInventors: Chih-Ming Chen, Xiu Xiu Cheng, Steve Jan, Joseph Chou
-
Patent number: 6106862Abstract: An analgesic controlled release dosage form containing: (a) 40-80 weight percent of an analgesic; (b) 10-30 weight percent of a pharmaceutically acceptable filler; and (c) 10-30 weight percent of a carrier base wherein the carrier base is formed from a high molecular weight hydroxypropyl methylcellulose, a water soluble binder and optionally a water insoluble binder.Type: GrantFiled: August 13, 1998Date of Patent: August 22, 2000Assignee: ANDRX CorporationInventors: Chih-Ming Chen, Joseph Chou, David Wong
-
Patent number: 6099862Abstract: A controlled release pharmaceutical tablet containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable coating membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core.Type: GrantFiled: August 31, 1998Date of Patent: August 8, 2000Assignee: ANDRX CorporationInventors: Chih-Ming Chen, Xiu Xiu Cheng, Joseph Chou, Steve Jan